Dinamica indicilor clinici și paraclinici sub acțiunea regimurilor antiretrovirale de linia întâi în Republica Moldova

Pavel Micsanschi; Ina Bîstrițchi; Irina Russu; Stela Cojocaru; Mirabela Maximciuc; Iurie Climasevschi; Tiberiu Holban; Angela Nagîţ

The dynamics of clinical and paraclinical indices under the action of first-line antiretroviral regimes in the Republic of Moldova

Authors

Pavel Micsanschi Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0002-1809-0767
Ina Bistritchi Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0003-3626-5281
Irina Russu Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0002-2759-3171
Stela Cojocaru Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0002-1420-8772
Mirabela Maximciuc Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0003-1127-742X
Iurie Climasevschi Dermatology and Communicable Diseases Hospital
Tiberiu Holban Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0003-0923-3129
Angela Nagit Dermatology and Communicable Diseases Hospital https://orcid.org/0009-0000-5619-4009

Keywords:

ART - antiretroviral treatment, HIV - human immunodeficiency virus

Abstract

In the last years, various ART regimens are available for the treatment of HIV+ patients, which have shown efficiency and safety in clinical trials. Objective of the study – Evaluation of clinical and paraclinical indices on of first-line ART regimens. A descriptive (retrospective) study described on 120 patients, eligible for the study being primary detected HIV infection who started first-line ART, with age average of 32 years. ART regimens initiated were: TDF/FTC/EFV-91 patients, TDF/3TC/ EFV-13, 3TC/NVP/d4T-5, AZT/3TC/EFV-7, AZT/3TC NFV-1, AZT/3TC /NVP-3 being monitored virologically, immunologically and clinically for 1, 2, 3 years of treatment. Out of the 120 patients, 54 (45%) were up to 30 years, out of which 83% had the infection transmitted sexually. Out of all the patients, 68 was late presented, out of which 18 were detected in the AIDS stage. Opportunistic infections mainly present were: oropharyngeal candidiasis in 64, pulmonary tuberculosis in 17, Herpes Zoster in 10, Wasting syndrome in 20, encephalopathy HIV-1, TB-17. Detected comorbidities were: chronic viral hepatitis B in 14, chronic viral hepatitis B+C – in 1 (0.83%), chronic viral hepatitis C – 24 patients. Diagnosed concomitant diseases of the respiratory tract - 24 patients, concomitant diseases of the digestive tract - 35 patients. The study showed the necessity of early identification and promptly initiation of ART, patient adherence to therapy so as to optimize treatment outcome and contribute to quality of life and reduction of HIV transmission.

References

1. Edwards J., Stephen R., Hall H. Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens, AIDS. 2018 Jan 14;32(2):261-266. PMID: 29112076; PMCID: PMC5736462. https://doi.org/10.1097/QAD.0000000000001668

2. Elzi L., Erb S., Furrer H. Adverse events of raltegravir and dolutegravir, AIDS. 2017 Aug 24;31(13):1853-1858. PMID: 28692533; PMCID: PMC5566167. https://doi.org/10.1097/QAD.0000000000001590

3. European AIDS Clinical Society. EACS Guidelines, Version 11.1. 2022: 7-9 [https://www.aidsactioneurope.org/sites/default/files/599-0_0.pdf ] (vizitat la 03.09.2023).

4. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2021:29-35.[https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/AdultandAdolescentGL_2021_08_16.pdf ] (vizitat la 03.09.2023).

5. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, 2022:15-17 [https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf ] (vizitat la 03.09.2023).

6. Kennedy-Martin T., Curtis S., Faries D. A. Literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results, Trials. 2015 Nov 3;16:495. PMID: 26530985; PMCID: PMC4632358. https://doi.org/10.1186/s13063-015-1023-4

7. Llibre J., Montoliu A., Miró J. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort, HIV Med. 2019 Mar;20(3):237-247. Epub 2019 Jan 27. PMID: 30688007. https://doi.org/10.1111/hiv.12710

8. Mondi A , Cozzi-Lepri A., Tavelli A. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort, J Int AIDS Soc. 2019 Jan;22(1):e25227. PMID: 30663278; PMCID: PMC6340053.

https://doi.org/10.1002/jia2.25227

9. Monitorizarea controlului infecției HIV în Republica Moldova, anul 2022: 9-21 [https://sdmc.md/wp-content/uploads/2023/08/Raport-monitorizare-HIV_a.-2022-5.pdf ] (vizitat la 02.09.2023).

10. Moore D., Goodall R., Ives N. How generalizable are the results of large randomized controlled trials of antiretroviral therapy, HIV Med. 2000 Jul;1(3):149-54. https://doi.org/10.1046/j.1468-1293.2000.00019.x. PMID: 11737343. https://doi.org/10.1046/j.1468-1293.2000.00019.x

11. UNAIDS Global AIDS Update 2022: 1-6 [https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf] (vizitat la 02.09.2023).

12. Veloso M., Pascom A., Duarte E. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir, AIDS. 2019 Aug 1;33(10):1663-1668. PMID: 31082860. https://doi.org/10.1097/QAD.0000000000002254

13. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2nd ed. Geneva, Switzerland: WHO, 2016: 119-150 [https://iris.who.int/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1] (vizitat la 02.09.2023).

14. World health statistics 2023: monitoring health for the SDGs, sustainable development goals; Global report, 19 May 2023: 13-15 [file:///C:/Users/user/Downloads/9789240074323-eng%20(1).pdf] (vizitat la 02.09.2023).

15. Yu Y., Luo D., Chen X. Medication adherence to antiretroviral therapy among newly treated people living with HIV, BMC Public Health. 2018 Jul 4;18(1):825. PMID: 29973167; PMCID: PMC6030792. https://doi.org/10.1186/s12889-018-5731-z

16. Zenu S., Tesema T., Reshad M. Determinants of first-line antiretroviral treatment failure among adult patients on treatment in Mettu Karl Specialized Hospital, South West Ethiopia; a case control study. PLoS One. 2021 Oct 22;16(10):e0258930. PMID: 34679085; PMCID: PMC8535443. https://doi.org/10.1371/journal.pone.0258930

Downloads

PDF (Romanian)

Published

2026-04-15

Issue

No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a

Section

Articles

License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

[1]

Micsanschi, P. et al. 2026. The dynamics of clinical and paraclinical indices under the action of first-line antiretroviral regimes in the Republic of Moldova. Public Health Economy and Management in Medicine. 3(96) (Apr. 2026), 53–59.

Download Citation

Most read articles by the same author(s)

Irina Russu, Mariana Avricenco, Ina Bistritchi, Nina Tamojnic-Mazureac, Adelina Butnaru, Tiberiu Holban, The evolution of liver fibrosis in patients with viral hepatitis C after treatment with direct-acting antiviral drugs , Public Health Economy and Management in Medicine: No. 2(104) (2025): Supliment. Al VI-lea Congres Național de Gastroenterologie și Hepatologie din Republica Moldova cu participare internațională
Nina Tamojnic-Mazureac, Tiberiu Holban, Irina Russu, Ina Bistritchi, Valentina Poting-Rascov, Elena Golovco, Victoria Bulgac, Antiviral treatment of viral hepatitis C in patients with HIV infection , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Gheorghe Ivanov, Irina Russu, Reconstructive anterior segment surgery , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”
Mirabela Maximciuc, Ina Bistritchi, Irina Russu, Stela Cojocaru, Valentina Poting-Rascov, Natalia Dubineanschi, Pavel Micsansch, Tiberiu Holban, Mariana Avricenco, Andrian Osipov, Clinical and paraclinical features of chronic hepatitis B virus infection and response to antiviral therapy , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Mariana Avricenco, Irina Russu, Tiberiu Holban, Influence of direct acting antivirals with/without ribavirin on hematological parameters in cirrhosis with HCV , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Irina Russu, Tiberiu Holban, Mariana Avricenco, Mirabela Maximciuc, Ina Bîstrițchi, Stela Cojocaru, Nina Tamojnic-Mazureac, Valentina Poting-Rascov, Pavel Micsanschi, Natalia Dubineanschi, Natalia Culiuc, Andrian Osipov, Efficacy of antiviral treatment with Velpatasvir + Sofosbuvir and Glecaprevir + Pibrentasvir in patients with chronic VHC , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Liviu Iarovoi, Angela Nagit, Nicoleta Minzatean, Pavel Micsanschi, Lilia Cojuhari, Lilia Baba, Vasile Lazar, Tiberiu Holban, Cryptococcal meningitis in patients with HIV/AIDS , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Tiberiu Holban, Cuvânt inainte , Public Health Economy and Management in Medicine: No. 3(96) (2023): Supliment. Conferința națională de boli infecțioase cu participare internațională ,,Realități și perspective în patologia infecțioasă” , Ediția a VIII-a
Gheorghe Ivanov, Irina Russu, Refractive lens exchange , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”

The dynamics of clinical and paraclinical indices under the action of first-line antiretroviral regimes in the Republic of Moldova

Authors

Keywords:

Abstract

References

Downloads

Published

Issue

Section

License

How to Cite

Most read articles by the same author(s)

Similar Articles

Language

issn

oa cc-by-nc-sa

road-issn

crossref member

ibn